Managing Metastatic Thymoma With Metabolic and Medical Therapy: A Case Report

Matthew C L Phillips, Deborah K J Murtagh, Sanjay K Sinha, Ben G Moon, Matthew C L Phillips, Deborah K J Murtagh, Sanjay K Sinha, Ben G Moon

Abstract

Thymomas consist of neoplastic thymic cells intermixed with variable numbers of non-neoplastic lymphocytes. Metastatic thymomas are typically managed with non-curative chemotherapy to control tumor-related symptoms; no prolonged survival is expected. Metabolic-based approaches, such as fasting and ketogenic diets, target cancer cell metabolism by creating an increased reliance on ketones while decreasing glucose, glutamine, and growth factor availability, theoretically depriving cancer cells of their metabolic fuels while creating an unfavorable environment for cancer growth, which may be beneficial in metastatic thymoma. We report the case of a 37-year-old woman with myasthenia gravis, diagnosed with an inoperable type AB, stage IVA thymoma, who pursued a metabolic intervention consisting of periodic fasting (7-day, fluid-only fasts every 1-2 months), combined with a modified ketogenic diet on feeding days, for 2 years. Fasting-related adverse effects included cold intolerance, fatigue, and generalized muscle aches, all of which resolved during the second year. She experienced two myasthenia relapses, each associated with profoundly reduced oral intake, marked weight loss, and tumor regression-the first relapse was followed by a 32% decrease in tumor volume over 4 months, the second relapse by a dramatic 96% decrease in tumor volume over 4 months. The second relapse also required prednisone to control the myasthenia symptoms. We hypothesize that 2 years of fasting and ketogenic diet therapy metabolically weakened the neoplastic thymic cell component of the thymoma, "setting the stage" for immune activation and extreme energy restriction to destroy the majority of cancer cells during both relapses, while prednisone-induced apoptosis eradicated the remaining lymphocytic component of the thymoma during the second relapse. This case is unique in that a metabolic-based fasting and ketogenic diet intervention was used as the primary management strategy for a metastatic cancer in the absence of surgery, chemotherapy, or radiotherapy, culminating in a near-complete regression. Nearly 3 years after being diagnosed with inoperable metastatic cancer, our patient shows no signs of disease and leads a full and active life.

Keywords: cancer; fasting; ketogenic diet; metastatic thymoma; prednisone.

Copyright © 2020 Phillips, Murtagh, Sinha and Moon.

Figures

Figure 1
Figure 1
Pleural biopsy histological images showing (A) H&E stain, (B) 20×P63 stain (highlighting epithelial cell nuclei), (C) 20×AE1/AE3 stain (highlighting epithelial cell cytoplasm), and (D) 20×CD45 stain (highlighting lymphoid cells).
Figure 2
Figure 2
Patient timeline.
Figure 3
Figure 3
CT chest (coronal and axial views, bulk of tumor circled in red) showing total tumor volumes at diagnosis, 8, 12, 25, and 29 months post-diagnosis.

References

    1. Levine G, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. (1978) 9:495–515. 10.1016/s0046-8177(78)80131-2
    1. Verley J, Hollmann K, Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases. Cancer. (1985) 55:1074–86. 10.1002/1097-0142(19850301)55:5<1074::aid-cncr2820550524>3.0.co2-t
    1. Falkson C, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak D, et al. . The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. (2009) 4:911–19. 10.1097/jto.0b013e3181a4b8e0
    1. Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev. (2013) 22:75–87. 10.1183/09059180.00007312
    1. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. (2003) 76:878–84. 10.1016/s0003-4975(03)00555-1
    1. Gadalla S, Rajan A, Pfeiffer R, Kristinsson S, Björkholm M, Landgren O, et al. . A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer. (2010) 128:2688–94. 10.1002/ijc.25583
    1. Seyfried T, Flores R, Poff A, D'Agostino D. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. (2013) 35:515–27. 10.1093/carcin/bgt480
    1. Epstein T, Gatenby R, Brown J. The Warburg effect as an adaptation of cancer cells to rapid fluctuations in energy demand. PLoS ONE. (2017) 12:e0185085. 10.1371/journal.pone.0185085
    1. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. (1955) 122:501–4. 10.1126/science.122.3168.501
    1. Wise D, Thompson C. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. (2010) 35:427–33. 10.1016/j.tibs.2010.05.003
    1. O'Flanagan C, Smith L, McDonell S, Hursting S. When less may be more: calorie restriction and response to cancer therapy. BMC Med. (2017) 15:106. 10.1186/s12916-017-0873-x
    1. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. 10.1016/j.cell.2011.02.013
    1. Turbitt W, Demark-Wahnefried W, Peterson C, Norian L. Targeting glucose metabolism to enhance immunotherapy: emerging evidence on intermittent fasting and calorie restriction mimetics. Front Immunol. (2019) 10:1402. 10.3389/fimmu.2019.01402
    1. Phillips M. Fasting as a therapy in neurological disease. Nutrients. (2019) 11:2501. 10.3390/nu11102501
    1. Magee B, Potezny N, Rofe A, Conyers R. The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci. (1979) 57:529–39. 10.1038/icb.1979.54
    1. Fine E, Miller A, Quadros E, Sequeira J, Feinman R. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. (2009) 9:14. 10.1186/1475-2867-9-14
    1. Freestyle FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System. (2019). Available online at: (accessed December 22, 2019).
    1. Mais D, Mulhall B, Adolphson K, Yamamoto K. Thymoma-associated autoimmune enteropathy: a report of two cases. Am J Clin Pathol. (1999) 112:810–15. 10.1093/ajcp/112.6.810
    1. Lee C, Raffaghello L, Brandhorst S, Safdie F, Bianchi G, Martin-Montalvo A, et al. . Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. (2012) 4:124ra27. 10.1126/scitranslmed.3003293
    1. Longo V, Mattson M. Fasting: molecular mechanisms and clinical applications. Cell Metab. (2014) 19:181–92. 10.1016/j.cmet.2013.12.008
    1. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS ONE. (2014) 9:e115147. 10.1371/journal.pone.0115147
    1. Colman R, Anderson R, Johnson S, Kastman E, Kosmatka K, Beasley T, et al. . Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. (2009) 325:201–4. 10.1126/science.1173635
    1. Cleary M, Grossmann M. The manner in which calories are restricted impacts mammary tumor cancer prevention. J Carcinog. (2011) 10:21. 10.4103/1477-3163.85181
    1. Rogozina O, Bonorden M, Grande J, Cleary M. Serum insulin-like growth factor-i and mammary tumor development in ad libitum-Fed, chronic calorie-restricted, and intermittent calorie-restricted MMTV-TGF- mice. Cancer Prev Res. (2009) 2:712–19. 10.1158/1940-6207.capr-09-0028
    1. Safdie F, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. . Fasting and cancer treatment in humans: a case series report. Aging. (2009) 1:988–1007. 10.18632/aging.100114
    1. de Groot S, Vreeswijk M, Welters M, Gravesteijn G, Boei J, Jochems A, et al. . The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. (2015) 15:652. 10.1186/s12885-015-1663-5
    1. Bauersfeld S, Kessler C, Wischnewsky M, Jaensch A, Steckhan N, Stange R, et al. . The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. (2018) 18:476. 10.1186/s12885-018-4353-2
    1. Klement R. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol. (2017) 34:132. 10.1007/s12032-017-0991-5
    1. Vernon L. William Bradley Coley, MD, and the phenomenon of spontaneous regression. Immunotargets Ther. (2018) 7:29–34. 10.2147/itt.s163924
    1. Jessy T. Immunity over inability: the spontaneous regression of cancer. J Nat Sci Biol Med. (2011) 2:43–9. 10.4103/0976-9668.82318
    1. Fukui T, Taniguchi T, Kawaguchi K, Yokoi K. Spontaneous regression of thymic epithelial tumours. Interact Cardiovasc Thorac Surg. (2013) 18:399–401. 10.1093/icvts/ivt496
    1. Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, et al. . Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer. (2002) 94:1414–20. 10.1002/cncr.10374
    1. Loehrer P, Wang W, Johnson D, Ettinger D. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an eastern cooperative oncology group phase II trial. J Clin Oncol. (2004) 22:293–99. 10.1200/jco.2004.02.047
    1. Kirkove C, Berghmans J, Noel H, Van de Merckt J. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin Oncol. (1992) 4:64–6. 10.1016/s0936-6555(05)80783-6
    1. Termeer A. Regression of invasive thymoma following corticosteroid therapy. Neth J Med. (2001) 58:181–4. 10.1016/s0300-2977(01)00090-0
    1. Barratt S, Puthucheary Z, Plummeridge M. Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms. Eur J Cardiothorac Surg. (2007) 31:1142–43. 10.1016/j.ejcts.2007.02.032
    1. Kobayashi Y, Fujii Y, Yano M, Sasaki H, Yukiue H, Haneda H, et al. . Preoperative steroid pulse therapy for invasive thymoma. Cancer. (2006) 106:1901–7. 10.1002/cncr.21875

Source: PubMed

3
Tilaa